Safety Committee Clears 15 mg/kg Dose, Entrada Advances DMD Study to Cohort 3
TRDA sits 21% above its 52-week low of $4.109.
Summary
An independent safety Data Monitoring Committee reviewed all safety and PK data from the eight patients in Cohort 2 of ELEVATE-45-201 and cleared Entrada to start Cohort 3 at 15 mg/kg, up from 10 mg/kg in Cohort 2 and 5 mg/kg in Cohort 1. That is a dose-escalation green light for ENTR-601-45 in exon 45-skipping Duchenne, and it keeps the program on its planned path after the positive Cohort 1 topline data reported October 14. Cohort 2 enrollment is now complete, with data expected in the first half of 2027 and Cohort 3 to follow. The company is funding operations into Q4 2027 on $193.0 million in cash, so this readout is the next real value inflection rather than a financing risk. Higher dose and exposure is where management expects meaningfully higher dystrophin production, so the Cohort 2 data in H1 2027 is the number that matters.
At the time of this announcement, TRDA was trading at $4.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $194.2M. The 52-week trading range was $4.11 to $16.45. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.